BACKGROUND: Although the high efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/lamivudine (DTG/3TC) in treatment-naïve people living with HIV (PLWH) have been well established, their metabolic effects remain a concern. RESEARCH DESIGN AND METHODS: We retrospectively analyzed 499 treatment-naïve PLWH who initiated BIC/FTC/TAF or DTG/3TC at Beijing Ditan Hospital between January 2021 and December 2023 to compare metabolic outcomes over a 48-week follow-up period. RESULTS: = 0.726). CONCLUSION: In this cohort of treatment-naïve PLWH, initiation of BIC/FTC/TAF or DTG/3TC achieved comparable metabolic outcomes, immunologic and virologic after 48 weeks, while BIC/FTC/TAF was associated with significantly increases in BMI.
Guo et al. (Mon,) studied this question.